Vidaza Indications/Uses





DCH Auriga
Full Prescribing Info
VIDAZA is indicated for treatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation (or acute myeloid leukemia with 20-30% bone marrow blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification), Adult patients aged 65 years or older who are not eligible for haematopoietic stem cell transplantation (HSCT) with AML with >30% marrow blasts according to the WHO classification, and chronic myelomonocytic leukemia.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in